These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 18506620)

  • 1. Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer.
    Han HS; Ro J; Lee KS; Nam BH; Seo JA; Lee DH; Lee H; Lee ES; Kang HS; Kim SW
    Breast Cancer Res Treat; 2009 May; 115(2):335-42. PubMed ID: 18506620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy.
    Iwamoto T; Hara F; Uemura Y; Mukai H; Watanabe T; Ohashi Y
    Breast Cancer Res Treat; 2020 Jul; 182(2):325-332. PubMed ID: 32462261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea.
    Najafi S; Djavid GE; Mehrdad N; Rajaii E; Alavi N; Olfatbakhsh A; Najafi M; Bahrami A; Heidari K
    Menopause; 2011 Feb; 18(2):208-12. PubMed ID: 21037487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens.
    Pérez-Fidalgo JA; Roselló S; García-Garré E; Jordá E; Martín-Martorell P; Bermejo B; Chirivella I; Guzman C; Lluch A
    Breast Cancer Res Treat; 2010 Feb; 120(1):245-51. PubMed ID: 19575291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study.
    Yoo C; Yun MR; Ahn JH; Jung KH; Kim HJ; Kim JE; Park JY; Park KO; Yoon DH; Kim SB
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):565-75. PubMed ID: 23842722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane.
    Tham YL; Sexton K; Weiss H; Elledge R; Friedman LC; Kramer R
    Am J Clin Oncol; 2007 Apr; 30(2):126-32. PubMed ID: 17414460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
    Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y
    Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
    von Minckwitz G; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; Untch M
    J Clin Oncol; 2010 Apr; 28(12):2015-23. PubMed ID: 20308671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients.
    Zhou WB; Yin H; Liu XA; Zha XM; Chen L; Dai JC; Tao AD; Chen L; Ma JJ; Ling LJ; Wang S
    BMC Cancer; 2010 Jun; 10():281. PubMed ID: 20540745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer.
    Jeong JH; Jung SY; Park IH; Lee KS; Kang HS; Kim SW; Kwon Y; Kim EA; Ko KL; Nam BH; Lee S; Ro J
    Invest New Drugs; 2012 Feb; 30(1):408-16. PubMed ID: 20922557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resumption or persistence of menstruation after cytotoxic chemotherapy is a prognostic factor for poor disease-free survival in premenopausal patients with early breast cancer.
    Park IH; Han HS; Lee H; Lee KS; Kang HS; Lee S; Kim SW; Jung S; Ro J
    Ann Oncol; 2012 Sep; 23(9):2283-2289. PubMed ID: 22377562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer.
    Jinno H; Sakata M; Hayashida T; Takahashi M; Mukai M; Ikeda T; Kitagawa Y
    Ann Oncol; 2010 Jun; 21(6):1262-1266. PubMed ID: 19854722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
    Mackey JR; Martin M; Pienkowski T; Rolski J; Guastalla JP; Sami A; Glaspy J; Juhos E; Wardley A; Fornander T; Hainsworth J; Coleman R; Modiano MR; Vinholes J; Pinter T; Rodríguez-Lescure A; Colwell B; Whitlock P; Provencher L; Laing K; Walde D; Price C; Hugh JC; Childs BH; Bassi K; Lindsay MA; Wilson V; Rupin M; Houé V; Vogel C;
    Lancet Oncol; 2013 Jan; 14(1):72-80. PubMed ID: 23246022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer.
    Joerger M; Ess S; Dehler S; Savidan A; Bouchardy C; Frick H; Konzelmann I; Thürlimann B
    Swiss Med Wkly; 2012; 142():w13571. PubMed ID: 22495767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel.
    Berliere M; Dalenc F; Malingret N; Vindevogel A; Piette P; Roche H; Donnez J; Symann M; Kerger J; Machiels JP
    BMC Cancer; 2008 Feb; 8():56. PubMed ID: 18291033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
    J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
    Zambetti M; Mansutti M; Gomez P; Lluch A; Dittrich C; Zamagni C; Ciruelos E; Pavesi L; Semiglazov V; De Benedictis E; Gaion F; Bari M; Morandi P; Valagussa P; Luca G
    Breast Cancer Res Treat; 2012 Apr; 132(3):843-51. PubMed ID: 21750964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane.
    Okanami Y; Ito Y; Watanabe C; Iijima K; Iwase T; Tokudome N; Takahashi S; Hatake K
    Breast Cancer; 2011 Jul; 18(3):182-8. PubMed ID: 21394515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials.
    Loibl S; von Minckwitz G; Harbeck N; Janni W; Elling D; Kaufmann M; Eggemann H; Nekljudova V; Sommer H; Kiechle M; Kümmel S
    Breast Cancer Res; 2008; 10(5):R77. PubMed ID: 18796139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancer.
    Zhang XH; Hao S; Gao B; Tian WG; Jiang Y; Zhang S; Guo LJ; Luo DL
    Oncotarget; 2016 Dec; 7(51):84533-84543. PubMed ID: 27811367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.